Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced it has raised $115.1 million in a recent funding round from investors. This significant capital infusion is intended to advance the company's development of its investigational therapy, Haduvio™ (oral nalbuphine extended-release).
Trevi Therapeutics is dedicated to developing Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is notable as the first and only investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials with IPF chronic cough patients and RCC patients. The therapy operates on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors crucial in controlling chronic cough. Importantly, nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi is headquartered in New Haven, CT.
The $115.1 million in secured funding is expected to support the ongoing clinical development programs for Haduvio, including its late-stage trials, and to strengthen the company's operational capabilities as it moves towards potential regulatory submissions and commercialization. This investment highlights investor confidence in Trevi's innovative approach to addressing chronic cough, a condition with significant unmet medical needs.
This funding round positions Trevi Therapeutics to accelerate its mission of bringing Haduvio to patients. The company plans to leverage this capital to further its research and development efforts, expand its team, and prepare for future growth within the biopharmaceutical sector, ultimately aiming to provide a novel treatment option for patients suffering from debilitating chronic cough conditions.
